Where Does Uterine Cancer Spread to First?

Uterine cancer most commonly spreads first to the pelvic lymph nodes and the tissues immediately surrounding the uterus, including the cervix, ovaries, fallopian tubes, and vaginal cuff. From there, more distant lymph nodes and organs can become involved. The exact route depends heavily on the tumor’s type and grade, but the lymphatic system is the highway most uterine cancers take when they leave the organ where they started. Understanding these pathways matters because where the cancer goes shapes both the staging and the treatment options a patient faces.

Pelvic Lymph Nodes Are Usually the First Stop

The uterus drains through a network of lymphatic channels that feed into clusters of lymph nodes in the pelvis and, higher up, alongside the aorta. When uterine cancer cells break free from the primary tumor, these nodes are the likeliest first destination. A large meta-analysis found that roughly 8.5% of endometrial cancer patients have pelvic lymph node involvement without spread to the para-aortic nodes, while about 8.4% have both pelvic and para-aortic nodes involved simultaneously.¹ A smaller but meaningful group, around 2.6%, had cancer in the para-aortic nodes with clean pelvic nodes, suggesting that a minority of tumors skip the closer nodes entirely and seed higher up.

For patients with disease still confined to the uterus at diagnosis (clinical stage I), the numbers are lower but not negligible. About 6% had pelvic node involvement alone, and about 3% had both pelvic and para-aortic node disease.¹ These figures underscore why even apparently early-stage cancer warrants careful evaluation of lymph nodes. The skip pattern, where para-aortic nodes light up without pelvic involvement, is uncommon but real, running about 1% in stage I. It complicates the surgical approach because surgeons can’t assume that clean pelvic nodes mean the cancer hasn’t traveled further.

The Vagina and Nearby Pelvic Tissues

After lymph nodes, the vagina is one of the most common sites of recurrence, and it is also a common route of direct spread. The top of the vagina, called the vaginal apex or cuff, sits right where the uterus was removed, so cancer cells have very little distance to travel. In one study of patients with stage I disease, about 2% developed an isolated vaginal recurrence, and roughly 70% of those appeared at the vaginal apex.² While 2% sounds small, these recurrences can happen years after initial treatment and are a key reason many patients receive vaginal brachytherapy (a localized form of radiation) after surgery.

A broader study of recurrence patterns across all stages found that the vagina was involved in about 42% of relapses, making it the second most common site behind lymph nodes (46%).³ The peritoneum accounted for about 28% of recurrences, and the lungs for roughly 24%. What this tells you is that uterine cancer tends to recur locally and regionally before showing up in far-off organs, though distant spread can occur alongside or even instead of local recurrence in more aggressive tumor types.

Ovarian and Fallopian Tube Involvement

The ovaries sit close to the uterus and share some of its blood supply and lymphatic drainage, making them a natural early target. In a large retrospective study of over 1,200 endometrial cancer patients, about 10% had ovarian metastasis at the time of surgery.⁴ These patients were more likely to have deep invasion into the uterine wall, lymph node involvement, and elevated CA-125 levels (a blood marker often tracked in gynecologic cancers).

The fallopian tubes can also harbor cancer, though this is less frequently studied. A pathology series identified cases of endometrioid carcinoma involving both the uterus and the fallopian tube, sometimes with concurrent ovarian disease as well.⁵ Determining whether the ovarian or tubal tumor is a metastasis from the uterus or a separate primary cancer can be genuinely difficult and sometimes requires molecular testing. The distinction matters for treatment planning, because a separate primary ovarian cancer carries different implications than a uterine cancer that has simply spread to the ovary.

Peritoneal and Omental Seeding

Not all uterine cancers spread through lymphatics. Some shed cells directly into the abdominal cavity, a pattern called peritoneal dissemination. This is especially common in uterine serous carcinoma, an aggressive subtype that behaves more like ovarian cancer than like the more common endometrioid type. Serous carcinoma tends to shed cells even when the tumor appears superficial, and comprehensive staging surgery including examination of the omentum (the fatty apron draped over the intestines) is standard for this reason.⁶

Omental metastasis is not rare in high-grade uterine cancers. Research suggests that roughly a third of patients with type II endometrial cancer (which includes serous and clear-cell subtypes) have occult omental disease, meaning the omentum looks normal to the eye but harbors microscopic cancer. Adnexal involvement, positive peritoneal fluid samples, and peritoneal spread are all independent risk factors for finding cancer in the omentum.⁷ Carcinosarcoma, another aggressive variant, also shows high rates of positive peritoneal cytology, with one study finding it in about 31% of cases compared to 7% in high-grade endometrioid tumors.⁸

Distant Metastases to Lungs, Liver, and Beyond

When uterine cancer reaches distant organs through the bloodstream, the lungs are the most frequent landing site. A population-based study of uterine cancer patients with distant metastases at diagnosis found that about 62% had lung involvement, roughly 22% had liver metastases, about 13% had bone metastases, and around 3% had brain involvement.⁹ The lung predilection sets uterine cancer apart from ovarian cancer, which more often metastasizes to the liver. Bone and brain involvement, while less common, are recognized and can cause significant symptoms when they occur.

Atypical metastatic sites do appear in the medical literature, including the adrenal glands, soft tissue, and extra-abdominal lymph nodes such as those in the neck or groin. These are rare enough that they occasionally lead to diagnostic confusion, especially when a patient presents with a mass in an unusual location years after completing treatment for uterine cancer. The more typical recurrence pattern stays within the pelvis, abdomen, and lungs.

Why the Cancer’s Type Matters as Much as Its Location

Uterine cancer is not one disease. The most common form, endometrioid adenocarcinoma, tends to grow and spread more predictably: it invades the uterine wall, reaches local lymph nodes, and may eventually spread distantly. Low-grade versions of this tumor are often caught early and carry a favorable prognosis. High-grade endometrioid tumors behave more aggressively, with deeper wall invasion and higher rates of node involvement.

Serous carcinoma, as mentioned, acts quite differently. It can metastasize to the peritoneum and omentum even when it barely invades the uterine wall, making it harder to predict from imaging alone. Clear-cell carcinoma shares some of this aggressive behavior. Carcinosarcoma, a mixed tumor containing both carcinoma and sarcoma elements, follows yet another pattern: despite often showing less deep myometrial invasion than high-grade endometrioid tumors, it has significantly higher rates of peritoneal spread.⁸ Overall lymph node metastasis rates between carcinosarcoma and high-grade endometrioid cancer were similar in that study, at about 36% and 25% respectively, but the route and pattern of spread differed meaningfully.

Beyond histologic type, molecular classification is now influencing how doctors assess risk. The 2023 FIGO staging system for endometrial cancer incorporates molecular subtypes, recognizing that tumor biology can override what the anatomy alone suggests.¹⁰ For instance, a tumor with a p53-abnormal molecular profile may be upstaged even if it looks early by traditional measures, because that molecular signature predicts more aggressive behavior. Conversely, tumors with POLE mutations tend to have excellent outcomes and may be downstaged.¹¹ This represents a genuine shift in how oncologists think about spread risk: the molecular fingerprint of the tumor is now part of the formal staging system, not just an add-on.

Lymphovascular Space Invasion as an Early Warning

One of the strongest pathologic predictors that a uterine cancer is going to spread is something called lymphovascular space invasion, or LVSI. This is a microscopic finding where cancer cells are seen inside the small lymphatic or blood vessels within the uterine wall. It occurs in a minority of endometrial cancers, but when present, it signals a higher risk of finding cancer in the lymph nodes and of distant recurrence.¹²

The numbers are striking. One study found that patients whose tumors showed LVSI had more than eleven times the odds of lymph node metastasis compared to those without it.¹³ A multicenter study of early-stage endometrial cancer found that LVSI was independently associated with about a 2.4-fold increase in the risk of distant recurrence, even after accounting for other factors like age, tumor grade, and depth of invasion.¹⁴ Interestingly, that same study did not find LVSI to be a risk factor for local recurrence, only distant spread. In practical terms, this means that a patient whose pathology report mentions LVSI may be offered more aggressive adjuvant treatment to head off metastatic disease, even if the tumor appears confined to the uterus.

How Surgeons Map the Spread

Knowing where uterine cancer goes first has reshaped how surgeons approach the disease over the past two decades. The older approach involved removing as many pelvic and para-aortic lymph nodes as possible during hysterectomy, a procedure that provided thorough staging information but came with significant risks of complications like lymphedema (chronic swelling in the legs). The field has gradually moved toward a less extensive approach focused on sentinel lymph node mapping.¹⁵

A sentinel lymph node is the first node that drains the tumor site. If that node is free of cancer, the remaining nodes downstream are overwhelmingly likely to be clean as well.¹⁶ During surgery, a dye or tracer is injected near the tumor, and the surgeon identifies the first nodes that pick up the tracer. Only those nodes are removed and examined closely, often with special staining techniques that can catch tiny clusters of cancer cells (micrometastases) that routine examination would miss. Multiple studies have found that sentinel node mapping is not inferior to full lymph node removal for identifying patients with nodal disease, while significantly reducing surgical complications.¹⁷¹⁸

Imaging Tools for Detecting Spread

Imaging plays a key role in identifying where uterine cancer has traveled, both at initial diagnosis and during follow-up. MRI is the primary tool for evaluating how far the tumor extends within the uterus and pelvis, including cervical involvement and depth of wall invasion. PET/CT scans, which detect metabolically active cancer cells throughout the body, have proven particularly useful for detecting occult metastatic lesions that other imaging misses.¹⁹

A meta-analysis of PET/CT performance found high specificity for detecting lymph node metastasis, meaning the test is very good at confirming that cancer is present in a node when it flags one. However, its sensitivity is more moderate: it catches about seven in ten involved lymph nodes, meaning some positive nodes can be missed, particularly when the disease deposits are very small.²⁰ For detecting recurrence outside the pelvis, PET/CT performs better, with sensitivity above 90%. This makes PET/CT especially valuable when a patient’s blood markers are rising after treatment but conventional imaging looks normal. The updated 2023 FIGO staging system has further increased the role of MRI, since the new staging criteria require more precise characterization of how the tumor relates to specific structures like the uterine serosa versus the adnexa.²¹

How Treatment Follows the Spread

The treatment a patient receives is tightly linked to where and how the cancer has spread. For disease confined to the uterus, surgery alone or surgery followed by vaginal brachytherapy is often sufficient. Once lymph nodes are involved, the calculus changes substantially. Current practice for patients with node-positive disease increasingly combines chemotherapy, intensity-modulated radiation therapy, and immunotherapy agents. One approach described in the literature offers patients with stage IIIC disease (lymph node involvement) both chemotherapy and pelvic radiation, along with pembrolizumab or dostarlimab, as initial adjuvant treatment. Patients with measurable residual disease or high-risk subtypes receive chemoimmunotherapy with vaginal brachytherapy added when local recurrence risk is elevated.²²

The introduction of immune checkpoint inhibitors has been one of the most significant shifts in uterine cancer treatment in recent years, particularly for tumors that are mismatch-repair deficient (a molecular feature that makes the cancer more responsive to immunotherapy). These drugs are now used both in the advanced setting and increasingly in the adjuvant setting to prevent recurrence after surgery. For patients with peritoneal spread or omental involvement, the surgical approach may include omentectomy and peritoneal biopsies in addition to hysterectomy and node assessment, mirroring the comprehensive staging used in ovarian cancer.

Rare and Unexpected Metastatic Sites

While the pelvis, abdomen, and lungs account for the vast majority of uterine cancer spread, case reports and small series document metastases to sites that can catch both patients and their doctors off guard. Bone metastases, present in about 13% of patients who already have distant disease at diagnosis, can cause pain and fractures.⁹ Brain metastases are rarer, at around 3%, but carry serious implications for quality of life and prognosis. Adrenal, soft tissue, and extra-abdominal lymph node metastases also appear in the literature, sometimes years after the original diagnosis. These unusual presentations are most common in aggressive subtypes like serous carcinoma and carcinosarcoma, reinforcing the general principle that tumor biology is the primary driver of where cancer ends up spreading.

1
PubMed Central. Paraaortic lymph node metastasis in endometrial cancer patients: a comprehensive analysis of rates, survival outcomes, and risk factors through systematic review and meta-analysis
2
PubMed Central. Isolated vaginal recurrence in women with stage I endometrial cancer
3
PubMed. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis
4
PubMed. Prediction of high-risk factors for ovarian metastasis in patients with endometrial cancer: A large-sample retrospective case-control study
5
The American Journal of Surgical Pathology. Endometrioid Carcinoma Simultaneously Involving the Uterus and the Fallopian Tube: A Clinicopathologic Study of 13 Cases
6
PubMed Central. The role of omentectomy in the surgical treatment of uterine serous carcinoma
7
PubMed. Risk factors for omental metastasis and the effect of omentectomy on survival in type 2 endometrial cancer patients
8
PubMed Central. Comparison of spread patterns and survival outcomes in uterine carcinosarcoma versus grade 3 endometrioid endometrial cancer
9
PubMed. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes
10
PubMed. FIGO staging of endometrial cancer: 2023
11
PubMed. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution
12
PubMed. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer
13
PubMed Central. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer
14
PubMed Central. Lymphovascular Space Invasion in Early-Stage Endometrial Cancer (LySEC): Patterns of Recurrence and Predictors. A Multicentre Retrospective Cohort Study of the Spain Gynecologic Oncology Group – Section: 3.3. Patterns of Recurrence
15
PubMed Central. Lymph node evaluation in endometrial cancer: how did it change over the last two decades?
16
PubMed Central. Sentinel Lymph Node Mapping in Endometrial Cancer: A Comprehensive Review
17
PubMed Central. Sentinel node mapping in endometrial cancer
18
PubMed. Sentinel Lymph Node Mapping vs Systematic Lymphadenectomy for Endometrial Cancer: Surgical Morbidity and Lymphatic Complications
19
PubMed Central. Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature
20
Journal of Nuclear Medicine. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature
21
PubMed Central. The updated 2023 staging of endometrial cancer: tips for MRI interpretation
22
PubMed Central. Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy